Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ANIP

ANIP - ANI Pharmaceuticals Inc Stock Price, Fair Value and News

67.29USD-0.38 (-0.56%)Market Closed
Watchlist

Market Summary

USD67.29-0.38
Market Closed
-0.56%

ANIP Alerts

  • 1 major insider sales recently.
  • Big jump in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)

ANIP Stock Price

View Fullscreen

ANIP RSI Chart

ANIP Valuation

Market Cap

1.2B

Price/Earnings (Trailing)

63.65

Price/Sales (Trailing)

2.46

EV/EBITDA

11.33

Price/Free Cashflow

10.86

ANIP Price/Sales (Trailing)

ANIP Profitability

Operating Margin

82.47%

EBT Margin

4.08%

Return on Equity

4.34%

Return on Assets

2.08%

Free Cashflow Yield

9.21%

ANIP Fundamentals

ANIP Revenue

Revenue (TTM)

486.8M

Rev. Growth (Yr)

39.71%

Rev. Growth (Qtr)

-0.13%

ANIP Earnings

Earnings (TTM)

18.8M

Earnings Growth (Yr)

127.22%

Earnings Growth (Qtr)

-88.38%

Breaking Down ANIP Revenue

Last 7 days

5.7%

Last 30 days

5.3%

Last 90 days

16.2%

Trailing 12 Months

32.7%

How does ANIP drawdown profile look like?

ANIP Financial Health

Current Ratio

3.57

Debt/Equity

0.66

Debt/Cashflow

0.42

ANIP Investor Care

Shares Dilution (1Y)

8.78%

Diluted EPS (TTM)

0.84

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023358.7M401.4M449.4M486.8M
2022226.1M251.3M283.1M316.4M
2021213.2M213.4M212.5M216.1M
2020203.4M197.5M199.2M208.5M
2019208.0M215.1M215.7M206.5M
2018186.7M189.2M191.7M201.6M
2017144.7M158.1M167.8M176.8M
201678.1M89.9M108.5M128.6M
201563.9M76.7M79.3M76.3M
201435.4M35.9M45.5M56.0M
201317.8M18.7M21.5M30.1M
20125.4M10.4M15.4M20.4M
20112.0M1.5M944.9K435.2K
20101.6M1.9M2.2M2.5M
20090001.3M

Tracking the Latest Insider Buys and Sells of ANI Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 15, 2024
mutz christopher
sold (taxes)
-72,570
57.55
-1,261
head of rare disease
Feb 15, 2024
gutwerg ori
sold (taxes)
-71,592
57.55
-1,244
svp, generics
Feb 14, 2024
marken james g.
acquired
-
-
16,776
svp ops & prod dev
Feb 14, 2024
cook meredith
acquired
-
-
24,605
sr. vp, general counsel & sec.
Feb 14, 2024
gutwerg ori
acquired
-
-
24,605
svp, generics
Feb 14, 2024
mutz christopher
acquired
-
-
31,316
head of rare disease
Feb 14, 2024
carey stephen p.
acquired
-
-
35,790
svp & cfo
Feb 14, 2024
shanmugam muthusamy
acquired
-
-
22,367
head of r&d, coo-novitium ops
Feb 14, 2024
gassert chad
acquired
-
-
22,367
svp - corp. dev. & strategy
Feb 14, 2024
lalwani nikhil
acquired
-
-
134,216
president & ceo

1–10 of 50

Which funds bought or sold ANIP recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
reduced
-1.42
-29,765
437,095
-%
Feb 26, 2024
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
unchanged
-
-11,000
214,000
-%
Feb 16, 2024
GSA CAPITAL PARTNERS LLP
new
-
516,000
516,000
0.04%
Feb 16, 2024
HARBOUR INVESTMENTS, INC.
unchanged
-
-6.00
110
-%
Feb 15, 2024
BARCLAYS PLC
added
171
852,000
1,393,000
-%
Feb 15, 2024
CASTLEARK MANAGEMENT LLC
sold off
-100
-3,891,180
-
-%
Feb 15, 2024
JANE STREET GROUP, LLC
reduced
-31.61
-423,026
783,925
-%
Feb 15, 2024
Legal & General Group Plc
reduced
-5.01
-249,074
2,296,860
-%
Feb 15, 2024
Virtus Fund Advisers, LLC
unchanged
-
-2,540
47,972
0.30%
Feb 15, 2024
Virtus Investment Advisers, Inc.
unchanged
-
-35,971
679,270
0.51%

1–10 of 48

Are Funds Buying or Selling ANIP?

Are funds buying ANIP calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ANIP
No. of Funds

Unveiling ANI Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
6.31%
1,288,972
SC 13G
Feb 12, 2024
rubric capital management lp
5.51%
1,125,000
SC 13G
Jan 23, 2024
blackrock inc.
12.4%
2,524,660
SC 13G/A
Jan 17, 2024
esjay llc
4.6%
932,620
SC 13D/A
Dec 18, 2023
meridian venture partners ii gp, l.p.
8.1%
1,644,381
SC 13D/A
Dec 05, 2023
esjay llc
4.8%
982,620
SC 13D/A
Aug 18, 2023
meridian venture partners ii gp, l.p.
9.0%
1,819,259
SC 13D/A
Jan 26, 2023
blackrock inc.
11.4%
1,983,237
SC 13G/A
Jan 20, 2023
blackrock inc.
11.4%
1,983,237
SC 13G/A
Dec 12, 2022
meridian venture partners ii gp, l.p.
11.6%
2,019,259
SC 13D/A

Recent SEC filings of ANI Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Feb 29, 2024
10-K
Annual Report
Feb 29, 2024
8-K
Current Report
Feb 23, 2024
8-K
Current Report
Feb 20, 2024
4
Insider Trading
Feb 20, 2024
4
Insider Trading
Feb 16, 2024
4
Insider Trading
Feb 16, 2024
4
Insider Trading
Feb 16, 2024
4
Insider Trading
Feb 16, 2024
4
Insider Trading
Feb 16, 2024
4
Insider Trading

What is the Fair Value of ANIP?

Loading...
Disclaimer: Conduct thorough research and seek guidance from a certified financial advisor prior to finalizing any investment choices.

Peers (Alternatives to ANI Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
390.5B
93.0B
-3.60% -2.76%
11.11
4.2
6.46% 95.94%
150.2B
28.2B
-7.44% 18.02%
22.36
5.33
7.09% 2.52%
150.1B
46.5B
-3.76% -37.06%
-108.1
3.22
42.59% -114.62%
90.0B
27.1B
-17.13% -16.65%
15.9
3.32
-0.60% 23.36%
15.1B
15.8B
15.02% 26.90%
-27.07
0.96
6.17% 77.01%
MID-CAP
5.0B
1.7B
14.11% 18.79%
13.94
2.98
49.61% 324.78%
3.6B
8.8B
-0.23% 18.85%
-6.11
0.41
7.79% -163.11%
3.6B
4.7B
-2.94% -9.06%
-280.21
0.76
4.58% 90.97%
2.2B
644.4M
-0.28% 70.16%
16.28
3.48
29.14% 50.51%
SMALL-CAP
1.3B
700.5M
2.67% -
-0.9
1.83
16.26% -147.49%
26.4M
70.0M
-0.88% -54.80%
0.39
0.34
-19.54% 888.31%
23.6M
84.1M
58.23% -28.98%
-1.1
0.22
2882.68% -145.15%
16.9M
111.1M
-6.33% -18.68%
-1.06
0.15
-10.43% 84.90%
2.0M
20.0M
-35.83% -91.10%
-0.14
0.1
137.71% 66.04%

ANI Pharmaceuticals Inc News

Latest updates
MarketBeat11 hours ago
InvestorsObserver33 hours ago
Seeking Alpha28 Feb 202404:59 pm

ANI Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-0.1%13213211710794.0084.0074.0064.0061.0052.0049.0055.0057.0053.0048.0050.0048.0051.0054.0053.0057.00
Cost Of Revenue------------20.0025.0020.0021.0022.0018.0015.0016.0015.0020.00
Costs and Expenses9.7%12511410497.0092.0089.0087.0084.0085.0056.0064.0051.0057.0050.0060.0058.0053.0044.0045.0048.0046.00
  S&GA Expenses5.8%44.0042.0039.0036.0033.0030.0032.0029.0031.0017.0019.0018.0014.0016.0021.0014.0014.0014.0014.0013.0013.00
  R&D Expenses-11.3%10.0011.007.006.005.008.004.005.003.002.003.003.004.003.003.006.005.005.006.004.003.00
EBITDA Margin-0.6%0.23*0.23*0.18*0.12*0.05*-0.05*-0.05*-0.08*0.00*0.12*0.15*0.17*0.12*0.10*0.11*0.19*0.26*0.32*0.32*0.32*0.30*
Interest Expenses0.4%8.008.0011.004.007.003.006.006.004.002.002.002.002.002.002.002.002.001.002.000.003.00
Income Taxes-112.9%-0.212.00-1.001.00-1.47-3.62-3.90-5.80-6.74-2.68-4.00-0.011.00-0.40-1.40-2.90-2.820.00-0.650.002.00
Earnings Before Taxes-91.8%1.0012.005.002.00-5.73-12.22-18.82-25.90-30.85-7.13-18.150.00-2.340.00-13.80-9.90-7.654.006.001.007.00
EBT Margin39.0%0.04*0.03*-0.03*-0.10*-0.20*-0.31*-0.33*-0.36*-0.26*-0.13*-0.10*-0.08*-0.12*-0.16*-0.14*-0.04*0.02*0.08*0.10*0.09*0.10*
Net Income-88.4%1.0010.006.001.00-4.24-8.60-14.92-20.13-24.14-4.45-14.110.00-3.630.00-12.34-7.01-4.834.007.000.005.00
Net Income Margin29.6%0.04*0.03*-0.01*-0.07*-0.15*-0.24*-0.25*-0.28*-0.20*-0.10*-0.08*-0.07*-0.11*-0.12*-0.10*-0.01*0.03*0.08*0.08*0.07*0.08*
Free Cashflow39.5%42.0030.0018.0019.00-7.541.00-12.80-20.89-12.54-5.97-0.6920.00-7.82-3.3720.000.003.0020.003.0013.0026.00
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets1.6%904890859765760739751745772470480464461463465482457457447434431
  Current Assets4.5%520497459365344309322301322191192183170166157159188182169152153
    Cash Equivalents14.5%22119316268.0048.0056.0063.0077.0010015.0024.0025.008.0018.0028.0020.0062.0060.0041.0038.0043.00
  Inventory4.3%11110710410410596.0093.0083.0082.0062.0068.0060.0061.0059.0053.0053.0048.0046.0045.0042.0041.00
  Net PPE0.9%45.0044.0044.0043.0043.0043.0044.0053.0053.0040.0040.0041.0041.0040.0040.0040.0041.0040.0039.0038.0038.00
  Goodwill0%28.0028.0028.0028.0028.0028.0028.0028.0028.004.004.004.004.004.004.004.004.004.004.004.002.00
Liabilities2.7%447435425426422402414399413279288260265267274281244244239235233
  Current Liabilities8.3%14513412312699.0082.0096.0080.0088.0085.0089.0083.0079.0076.0079.0079.0062.00171167165166
  Long Term Debt-100.0%-28528528528628628628628718619016917217517818817665.0066.0067.0067.00
    LT Debt, Current0%1.001.001.001.001.001.001.001.001.0016.0015.0014.0013.0013.0012.0012.0010.004.004.003.003.00
    LT Debt, Non Current-0.1%28528528528528628628628628718619016917217517818817665.0066.0067.0067.00
Shareholder's Equity0.7%433430495408314399395391388222219204214195191201201213208200197
  Retained Earnings0.9%-80.13-80.88-90.41-96.25-97.29-92.60-83.63-68.30-47.76-23.44-18.99-4.89-4.97-1.34-1.7711.0018.0022.0019.0012.0011.00
  Additional Paid-In Capital1.5%514507495408404399395391388222219216214212209204201197195190187
Accumulated Depreciation----27.0033.0030.0027.0025.0023.0021.0020.0019.0018.00--------
Shares Outstanding-100.0%-18.0018.0016.0016.0016.0016.0016.0013.0012.0012.0012.0012.0012.0012.0012.0012.0012.0012.0012.0012.00
Float-------373---348---316---658--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations39.1%44,74032,16920,62621,424-4,4003,623-11,484-18,942-12,185-5,40224120,668-5,709-1,61420,8801,7104,80321,7934,74414,29127,232
  Share Based Compensation3.3%5,6215,4445,2494,3383,7373,8693,7563,2372,9682,8082,8441,8692,3932,3835,7362,4242,4442,4702,5931,7101,828
Cashflow From Investing-5.0%-4,779-4,553-6,826-2,353-3,142-9,814-604-2,178-82,213-583-21,950-737-2,119-5,809-2,848-57,546-1,374-1,932-3,958-20,285-407
Cashflow From Financing-417.4%-11,9183,75580,150-4,548-508-911-1,437-2,270179,444-3,02220,898-2,725-2,208-2,378-10,74413,891-766-7701,5801,206-27,946
  Dividend Payments0%406406407406407406407405190------------
  Buy Backs-65.5%2316705373,5491192394831,1181.0073.00468348---------

ANIP Income Statement

2023-12-31
Consolidated Statements of Operations - USD ($)
shares in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]   
Net Revenues$ 486,816,000$ 316,385,000$ 216,136,000
Operating Expenses   
Cost of sales (excluding depreciation and amortization)181,513,000138,785,000100,610,000
Research and development34,286,00022,318,00011,369,000
Selling, general, and administrative161,697,000124,044,00084,294,000
Depreciation and amortization59,791,00056,972,00047,252,000
Contingent consideration fair value adjustment1,426,0003,758,000500,000
Legal settlement expense008,750,000
Purified Cortrophin Gel pre-launch charges00780,000
Restructuring activities1,132,0005,679,0000
Intangible asset impairment charge0112,0002,374,000
Total Operating Expenses439,845,000351,668,000255,929,000
Operating Income (Loss)46,971,000(35,283,000)(39,793,000)
Other Expense, net   
Interest expense, net(26,940,000)(28,052,000)(11,922,000)
Other (expense) income, net(159,000)670,000(4,343,000)
Income (Loss) Before Expense (Benefit) for Income Taxes19,872,000(62,665,000)(56,058,000)
Income tax expense (benefit)1,093,000(14,769,000)(13,455,000)
Net Income (Loss)18,779,000(47,896,000)(42,603,000)
Dividends on Series A Convertible Preferred Stock(1,625,000)(1,625,000)(190,000)
Net Loss Available to Common Shareholders$ 17,154,000$ (49,521,000)$ (42,793,000)
Basic and Diluted Income (Loss) Per Share:   
Basic Income (Loss) Per Share (in dollars per share)$ 0.86$ (3.05)$ (3.40)
Diluted Income (Loss) Per Share (in dollars per share)$ 0.85$ (3.05)$ (3.40)
Basic Weighted-Average Shares Outstanding (in shares)18,00116,26012,596
Diluted Weighted-Average Shares Outstanding (in shares)18,19416,26012,596

ANIP Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current Assets  
Cash and cash equivalents$ 221,121$ 48,228
Current restricted cash05,006
Accounts receivable, net of $97,262 and $161,052 of adjustments for chargebacks and other allowances at December 31, 2023 and 2022, respectively162,079165,438
Inventories111,196105,355
Prepaid income taxes03,827
Assets held for sale8,0208,020
Prepaid expenses and other current assets17,4008,387
Total Current Assets519,816344,261
Non-current Assets  
Property and equipment, net44,59343,246
Deferred tax assets, net of deferred tax liabilities and valuation allowance90,71181,363
Intangible assets, net209,009251,635
Goodwill28,22128,221
Derivatives and other non-current assets12,07211,361
Total Assets904,422760,087
Current Liabilities  
Current debt, net of deferred financing costs850850
Accounts payable36,68329,305
Accrued royalties16,2769,307
Accrued compensation and related expenses23,78610,312
Accrued government rebates12,16810,872
Income taxes payable8,1640
Returned goods reserve29,67833,399
Current contingent consideration12,2660
Accrued expenses and other5,6065,394
Total Current Liabilities145,47799,439
Non-current Liabilities  
Non-current debt, net of deferred financing costs and current component284,819285,669
Non-current contingent consideration, net of current11,71835,058
Other non-current liabilities4,8091,381
Total Liabilities446,823421,547
Commitments and Contingencies (Note 15)
Mezzanine Equity  
Convertible Preferred Stock, Series A, $0.0001 par value, 1,666,667 shares authorized; 25,000 shares issued and outstanding at December 31, 2023 and 202224,85024,850
Stockholders’ Equity  
Common Stock, $0.0001 par value, 33,333,334 shares authorized; 20,730,896 shares issued and 20,466,953 outstanding at December 31, 2023; 17,643,497 shares issued and 17,494,466 shares outstanding at December 31, 202221
Class C Special Stock, $0.0001 par value, 781,281 shares authorized; 10,864 shares issued and outstanding at December 31, 2023 and 2022 respectively00
Preferred Stock, $0.0001 par value, 1,666,667 shares authorized; 0 shares issued and outstanding at December 31, 2023 and 2022, respectively00
Treasury stock, 263,943 shares of common stock, at cost, at December 31, 2023 and 149,031 shares of common stock, at cost, at December 31, 2022(10,081)(5,094)
Additional paid-in capital514,103403,901
Accumulated deficit(80,132)(97,286)
Accumulated other comprehensive income, net of tax8,85712,168
Total Stockholders’ Equity432,749313,690
Total Liabilities, Mezzanine Equity, and Stockholders’ Equity$ 904,422$ 760,087
ANIP
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations, including extended release and combination products. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group purchasing organizations. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
 CEO
 WEBSITEwww.anipharmaceuticals.com
 EMPLOYEES600

ANI Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for ANI Pharmaceuticals Inc? What does ANIP stand for in stocks?

ANIP is the stock ticker symbol of ANI Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ANI Pharmaceuticals Inc (ANIP)?

As of Thu Feb 29 2024, market cap of ANI Pharmaceuticals Inc is 1.2 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ANIP stock?

You can check ANIP's fair value in chart for subscribers.

What is the fair value of ANIP stock?

You can check ANIP's fair value in chart for subscribers. The fair value of ANI Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ANI Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ANIP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ANI Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether ANIP is over valued or under valued. Whether ANI Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact ANI Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ANIP.

What is ANI Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 29 2024, ANIP's PE ratio (Price to Earnings) is 63.65 and Price to Sales (PS) ratio is 2.46. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ANIP PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ANI Pharmaceuticals Inc's stock?

In the past 10 years, ANI Pharmaceuticals Inc has provided 0.108 (multiply by 100 for percentage) rate of return.